LARGE1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Up-regulation of LARGE has previously been proposed as a therapy for the secondary dystroglycanopathies: overexpression in cells compensates for defects in multiple dystroglycanopathy genes.